Can SHBG be high despite elevated insulin?

Sex hormone-binding globulin (SHBG) is a glycoprotein produced by the liver that serves as a biomarker of metabolic health and insulin sensitivity. While insulin is a well-established suppressor of hepatic SHBG production, clinical scenarios exist where SHBG remains elevated despite hyperinsulinemia, indicating the presence of potent overriding physiological signals.

Mechanistic explanations

Insulin regulates SHBG production through a complex transcriptional pathway in the liver.

• Transcriptional Suppression: The primary activator of the SHBG gene is Hepatocyte Nuclear Factor-4$\alpha$ (HNF4$\alpha$). Insulin suppresses SHBG by decreasing the expression and activity of HNF4$\alpha$. This occurs through the PI3K-AKT pathway, which upregulates sterol regulatory element-binding protein 1c (SREBP-1c). SREBP-1c binds to the HNF4A promoter, directly repressing its transcription.
• Lipogenesis Interference: Insulin also drives de novo lipogenesis in the liver. The accumulation of hepatic lipids, such as palmitate, further downregulates HNF4$\alpha$, leading to the characteristic low SHBG levels seen in fatty liver disease and metabolic syndrome.
• Inflammatory Modulation: In insulin-resistant states, elevated tumor necrosis factor-alpha (TNF-$\alpha$) activates NF-$\kappa$B, which also targets the HNF4A promoter to reduce SHBG synthesis.

Clinical and hormonal drivers

When SHBG is high despite elevated insulin, it suggests that secondary stimulatory signals are dominating the hepatic output.

• Thyroid Hormones: Hyperthyroidism is a major driver of high SHBG. Thyroid hormones (T3 and T4) stimulate the hepatic production of SHBG, often overriding the suppressive effects of insulin and resulting in high circulating levels even in insulin-resistant patients.
• Estrogen Exposure: High levels of estrogen—whether from oral hormone therapy, pregnancy, or liver dysfunction that impairs estrogen clearance—act as a powerful transcriptional activator for the SHBG gene in hepatocytes.
• Liver Delivery Patterns: In conditions like Type 1 diabetes, patients may have high systemic insulin from subcutaneous injections but relatively low portal (liver-directed) insulin. This "relative hepatic hypoinsulinemia" allows SHBG production to remain high because the liver does not receive the same suppressive signal as it would from endogenous insulin production.
• Genetic Variation: Specific polymorphisms in the SHBG gene can lead to constitutively higher production levels or altered protein half-life, which may persist regardless of insulin levels.

Bottom line

• Insulin normally suppresses SHBG by inhibiting the master transcription factor HNF4$\alpha$ via SREBP-1c and hepatic lipogenesis.
• Elevated SHBG in the context of high insulin is a significant clinical finding that typically points to overriding factors such as hyperthyroidism, excessive estrogen, relative hepatic hypoinsulinemia, or genetic variants.
• In a 73-year-old female, high SHBG despite elevated insulin should prompt an evaluation of thyroid function and a review of exogenous hormone use (e.g., HRT) or liver health.